Halozyme Therapeutics, Inc. (HALO) Posts Narrower than Expected Q1 Loss
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $110.19 -0.51%
EPS Growth %: +30.2%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +30.2%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q1 loss of ($0.10), $0.03 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $7.5 million versus the consensus estimate of $5.19 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
- Duluth Holdings Inc. (DLTH) Tops Q2 EPS by 49c
- Victoria's Secret & Co. (VSXY) Tops Q2 EPS by 20c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
